You're concerned about climate change. But chances are, you don't know what's really in your investment portfolio and whether your investments are helping or hurting the cause.
A new ranking is working to help change that.
Steve Proehl | Corbis Documentary | Getty Images Solar panels on Google headquarters in CaliforniaAs You Sow, a nonprofit foundation, has teamed up with Corporate Knights, a research and financial information products company, to rank 200 companies by how well they are making clean energy a priority.
Top 5 Clean Energy Stocks To Watch Right Now: On Assignment Inc.(ASGN)
Advisors' Opinion:- [By Motley Fool Transcribing]
On Assignment (NYSE:ASGN) Q4 2018 Earnings Conference CallFeb. 13, 2019 5:00 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Stephan Byrd]
Jefferies Financial Group started coverage on shares of ASGN (NYSE:ASGN) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $70.00 target price on the business services provider’s stock.
- [By Joseph Griffin]
ASGN (NYSE: ASGN) and Amn Healthcare Services (NYSE:AMN) are both mid-cap computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.
- [By Logan Wallace]
Insperity (NYSE: NSP) and ASGN (NYSE:ASGN) are both mid-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.
Top 5 Clean Energy Stocks To Watch Right Now: DepoMed Inc.(DEPO)
Advisors' Opinion:- [By Todd Campbell]
After updating investors on its restructuring and boosting its full-year guidance, shares of Depomed Inc. (NASDAQ:DEPO) were up 23.2% on Thursday.
- [By Shane Hupp]
Depomed Inc (NASDAQ:DEPO) has received an average rating of “Hold” from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $8.67.
- [By Joseph Griffin]
Depomed (NASDAQ:DEPO) dropped 0% during mid-day trading on Tuesday . The stock traded as low as $6.58 and last traded at $6.69. Approximately 3,739,419 shares traded hands during mid-day trading, an increase of 190% from the average daily volume of 1,287,687 shares. The stock had previously closed at $6.69.
- [By Joseph Griffin]
Depomed Inc (NASDAQ:DEPO) has been assigned a consensus recommendation of “Hold” from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $8.50.
Top 5 Clean Energy Stocks To Watch Right Now: Corium International, Inc.(CORI)
Advisors' Opinion:- [By Shane Hupp]
Get a free copy of the Zacks research report on Corium International (CORI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
Get Corium International alerts: Analysts Expect Corium International Inc (CORI) Will Post Earnings of -$0.39 Per Share (americanbankingnews.com) Aequus and Corium Join Forces to Advance Anti-Nausea Transdermal Patch (globenewswire.com) Corium International Inc (CORI) Expected to Post Quarterly Sales of $6.72 Million (americanbankingnews.com) Corium International Inc (CORI) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)CORI has been the subject of several research analyst reports. Zacks Investment Research cut Corium International from a “buy” rating to a “hold” rating in a research report on Thursday, April 5th. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 price objective on shares of Corium International in a research report on Tuesday, March 27th. ValuEngine upgraded Corium International from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Finally, BidaskClub cut Corium International from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $13.00.
- [By Chris Lange]
Corium International Inc. (NASDAQ: CORI) shares jumped on Friday after the company announced that it entered into a definitive merger agreement under which Gurnet Point Capital (GPC) will acquire Corium. Corium's board of directors has unanimously approved the transaction.
- [By Motley Fool Staff]
Corium International (NASDAQ:CORI) Q2 2018 Earnings Conference CallMay. 14, 2018 5:00 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
Top 5 Clean Energy Stocks To Watch Right Now: Leading Brands Inc(LBIX)
Advisors' Opinion:- [By Joseph Griffin]
Media headlines about Leading Brands (NASDAQ:LBIX) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Leading Brands earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.3549545541136 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Top 5 Clean Energy Stocks To Watch Right Now: Blueprint Medicines Corporation(BPMC)
Advisors' Opinion:- [By Todd Campbell]
Investors should also keep their enthusiasm in check because Loxo Oncology isn't alone in targeting TRK fusion and RET mutations: Roche Holdings (NASDAQOTH:RHHBY) could challenge it in TRK fusions and Blueprint Medicines (NASDAQ:BPMC) could compete with it in RET mutations.
- [By Shane Hupp]
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BPMC. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Blueprint Medicines by 57.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 680 shares in the last quarter. QS Investors LLC acquired a new position in Blueprint Medicines in the 4th quarter valued at about $173,000. First Mercantile Trust Co. acquired a new position in Blueprint Medicines in the 4th quarter valued at about $183,000. Tower Research Capital LLC TRC grew its position in Blueprint Medicines by 942.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,513 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 2,272 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new position in Blueprint Medicines in the 4th quarter valued at about $227,000. 97.79% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “BidaskClub Downgrades Blueprint Medicines (BPMC) to Hold” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3356624/bidaskclub-downgrades-blueprint-medicines-bpmc-to-hold.html.Blueprint Medicines Company Profile
- [By Motley Fool Transcribers]
Blueprint Medicines Corp (NASDAQ:BPMC)Q4 2018 Earnings Conference CallFeb. 26, 2019, 8:30 a.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Todd Campbell]
After clinical-stage competitor Loxo Oncology (NASDAQ:LOXO) presented impressive data at the American Society of Clinical Oncology (ASCO) meeting this weekend, shares in Blueprint Medicines (NASDAQ:BPMC) tumbled by as much as 16% on Monday.
No comments:
Post a Comment